Wednesday, 17 December 2014

Akers Biosciences, Inc. (AKER) - Product Pipeline Analysis, 2014 Update

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Akers Biosciences, Inc. (AKER) - Product Pipeline Analysis, 2014 Update

Summary

Akers Biosciences, Inc. (ABI) is a diagnostic product manufacturer. The company develops proprietary in vitro diagnostic technologies. Its products include BreathScan, CHUBE, METRON, PIFA PLUSS PF4, tri-cholesterol, IFA Chlamydia, PIFA Dengue Fever, PIFA Malaria, PIFA Syphilis, and others. ABI's technologies include testing platform technology, and sample preparation technology. The company's testing platform technologies include MPC biosensor, particle immunofiltration assay, rapid enzymatic assay, minDNA, and synthetic macrocycle complex. ABI is headquartered in New Jersey, the US.

To Browse a Full Report with Toc
: http://www.researchmoz.us/akers-biosciences-inc-aker-product-pipeline-analysis-2014-update-report.html

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Akers Biosciences, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:


- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

To Browse a Full Report with Toc:
http://www.researchmoz.us/akers-biosciences-inc-aker-product-pipeline-analysis-2014-update-report.html

All Reports of this Category Here:
http://www.researchmoz.us/medical-equipments-market-reports-109.html

About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US:



For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463

No comments:

Post a Comment